Intrinsiqq
908 Devices Inc. logo

908 Devices Inc. Quality Score

MASS

⊜ Compare
Quality51

Valuation is the primary weakness (avg 20/100). Growth is the relative bright spot.

Broad-market heuristics · Not a buy/sell signal

Valuation and growth

Earnings Multiple
0/100
-11.5x

Negative earnings, no valuation support

Cash Flow Multiple
40/100
743.0x

Above 30x, cash flow yield is thin

Revenue Growth
70/100
6.7%

5–10% CAGR, steady but not exceptional

Cash Flow Growth
60/100
Just turned +

Recently turned FCF-positive, capex cycle finishing, CAGR not yet meaningful

Business Quality & Capital Allocation

Share Dilution
0/100
19.8%

Heavy dilution above 5%

Margin Trend
100/100
+11.5pp

Expanded 3+pp, strong improvement

Capital Structure
100/100
-$97M

Net cash position, no leverage concern

2022
$188M
$20.0M
2023
$146M
$6.00M
2024
$70.0M
$7.00M
2025
$113M
$5.00M
TTM
$102M
$4.00M
CashDebt
Return on Capital
0/100
-22.0%

Below 8%, may not cover cost of capital

Customize WeightsPremiumUpgrade

908 Devices (MASS) quality: score, margins and returns

908 Devices (MASS) scores 51/100 on Intrinsiqq's quality score (a mixed business), a weighted blend of 6 metrics each scored 0 to 100, on -64.0% operating margins and -22.0% ROIC. Every metric is computed from SEC filings; this is analysis, not investment advice.

Frequently asked

Is 908 Devices (MASS) a high-quality business?+

908 Devices scores 51 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which rates it a mixed business on these measures. Recent figures include a -64.0% operating margin and a -22.0% return on invested capital. Quality and price are separate questions: even a great business can be a poor investment if you overpay, so read this score alongside the valuation. The metric-by-metric breakdown is on this scorecard.

What does 908 Devices's quality score measure?+

Intrinsiqq's quality score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, change in share count, and balance-sheet strength, each computed from MASS's SEC filings rather than opinion or sentiment. A higher score means a more durable, capital-efficient business; it is not a buy or sell signal. Open each metric on this page to see exactly where 908 Devices scores well and where it falls behind.

What is 908 Devices's return on invested capital (ROIC)?+

908 Devices earns about -22.0% on its invested capital, which is weak. ROIC measures how much profit a company generates per dollar put to work; sustained ROIC above its cost of capital is one of the clearest signs of a real competitive moat. Compare it to MASS's margins and growth on this scorecard to judge durability.

How profitable is 908 Devices?+

908 Devices runs an operating margin of about -64.0% and a net margin of about -57.0%. Revenue has grown at roughly 15.9% a year recently. High, stable margins usually point to pricing power and operating discipline. Margins are most telling next to growth and returns on capital, all of which feed this quality score. This is analysis from SEC filings, not investment advice.

How the market compares: US profitability statistics

SourceQuality score computed from the 10-Q filed 7 Aug 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 12 Aug 2026. How this is calculated.

Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically. Checks use broad-market heuristics, so sector norms may differ, and the valuation checks are more cyclical than the quality checks.

Peers

Laboratory Analytical Instruments · Pick stocks to compare with MASS

CompareIntrinsic value
HBIOHarvard Bioscience, Inc.
$8.61-0.69%15
LABStandard Biotools Inc.
$0.62+1.38%35
RPIDRapid Micro Biosystems, Inc.
$0.68-1.59%30
BNGOBionano Genomics Inc.
$1.19-0.83%33
PRPOPrecipio Inc.
$19.57+5.10%57
SEERSeer, Inc.
$1.70-1.73%35
LCTCLifeloc Technologies Inc.
$3.50+0.00%11
EYPTEyePoint Pharmaceuticals Inc.
$0.40+0.00%10

Held by ETFs

MASS is in 8 US ETFs. The largest of them, with MASS's weight in each:

Spot a number that looks wrong? Check it in MASS's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing MASS

Create a free account and get 14 days of Premium: every stock and every tool.

  • Unlimited stocks
  • Stock screener
  • Portfolio tracker
  • Editable DCF
  • Compare side by side
  • Unlimited alerts

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

SectorsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.